Vitamin D 3 [phsu, strd, vita]
Supplementation [topp]
adverse effects [ftcn]
Lipids [lipd]
Hormone Replacement Therapy, Post-Menopausal [topp]
Objective [inpr]
Short-term [tmco]
effects [qlco]
Hormone Replacement Therapy, Post-Menopausal [topp]
Serum lipids NOS [lbpr]
Well [qlco]
Known [qlco]
Suggest [idcn]
Cholecalciferol [phsu, strd, vita]
Vitamin D 3 [phsu, strd, vita]
PREVENT [phsu]
Osteoporosis, Post-Menopausal [dsyn]
influential [idcn]
Vitamin D 3 [phsu, strd, vita]
Serum lipids NOS [lbpr]
Poorly [qlco]
Known [qlco]
Long-Term Effects [phpr]
Hormone replacement therapy [topp]
Vitamin D 3 [phsu, strd, vita]
Concentrations [menp]
Serum lipids NOS [lbpr]
Study [mnob]
Population Based Study [resa]
prospective [resa]
Design [acty]
Methods [inpr]
Women [popg]
randomized [resa]
treatment [ftcn]
Group [idcn]
Hormone replacement therapy [topp]
Sequential [idcn]
Combination [qlco]
mg% [qnco]
Oestradiol valerate [horm, phsu, strd]
mg% [qnco]
Cyproterone Acetate [phsu, strd]
vit d [orch, phsu, vita]
Vitamin D 3 [phsu, strd, vita]
IU/day [qnco]
III [inpr]
Hormone replacement therapy [topp]
vit d [orch, phsu, vita]
Above [spco]
placebo [topp]
calcium lactate 500 MG [clnd]
Women [popg]
COMPLETED [qlco]
Study [mnob]
treatment [ftcn]
serum concentration [qnco]
Low Density Lipoprotein Cholesterol [bacs, strd]
Decreased [qnco]
Hormone replacement therapy [topp]
Group [idcn]
P NOS [aapp, imft]
Hormone replacement therapy [topp]
vit d [orch, phsu, vita]
Group [idcn]
P NOS [aapp, imft]
Increased [qnco]
vit d [orch, phsu, vita]
Group [idcn]
P NOS [aapp, imft]
Unchanged [fndg]
placebo [topp]
Group [idcn]
Concentrations [menp]
Total Cholesterol [lbpr]
Decreased [qnco]
Hormone replacement therapy [topp]
Group [idcn]
P NOS [aapp, imft]
Hormone replacement therapy [topp]
vit d [orch, phsu, vita]
Group [idcn]
P NOS [aapp, imft]
Group [idcn]
serum concentration [qnco]
High Density Lipoprotein Cholesterol [bacs, lipd]
Decreased [qnco]
vit d [orch, phsu, vita]
Group [idcn]
P NOS [aapp, imft]
Hormone replacement therapy [topp]
vit d [orch, phsu, vita]
Group [idcn]
P NOS [aapp, imft]
placebo [topp]
Group [idcn]
4 5 [qnco]
P NOS [aapp, imft]
Hormone replacement therapy [topp]
Group [idcn]
high density/low density lipoprotein ratio [lbtr]
Lipoprotein [aapp, bacs]
Increased [qnco]
Hormone replacement therapy [topp]
Group [idcn]
P NOS [aapp, imft]
Decreased [qnco]
vit d [orch, phsu, vita]
Group [idcn]
P NOS [aapp, imft]
Occurred [acty]
Group [idcn]
Addition [ftcn]
serum triglycerides [lbpr]
Increased [qnco]
Group [idcn]
P NOS [aapp, imft]
Long-Term Effect [phpr]
Hormone replacement therapy [topp]
Sequential [idcn]
Oestradiol valerate [horm, phsu, strd]
Cyproterone Acetate [phsu, strd]
serum lipid [lbpr]
Concentrations [menp]
Addition [ftcn]
Suggest [idcn]
Vitamin D 3 [phsu, strd, vita]
Supplementation [topp]
Unfavorable [qlco]
effects [qlco]
Lipids [lipd]
postmenopausal [tmco]
Women [popg]
PurE [moft]
Vitamin [orch, phsu, vita]
dg [qnco]
treatment [ftcn]
Increased cholesterol [fndg]
serum low density lipoprotein [lbpr]
effects [qlco]
Hormone replacement therapy [topp]
serum low density lipoprotein [lbpr]
Cholesterol [bacs, strd]
Content [menp]
Reduced [qlco]
Oestradiol valerate [horm, phsu, strd]
Combined [qlco]
Vitamin D 3 [phsu, strd, vita]
Relevance [qlco]
Associations [menp]
Cardiovascular morbidity [dsyn]
Established [qlco]
